Wayme State University (WSU) has been an active institutional member of the Southwest Oncology Group (SWOG) since 1972. We have enrolled over 4500 patients onto clinical trials and remain one of the highest contributing institutions by meeting and exceeding patient accrual goals in a continuous and consistent manner. Over the years, faculty members have played an important role in support of SWOG, providing leadership in both the administrative and scientific functions of the group. The clinical research program in cancer at WSU is organized along the lines of multidisciplinary disease oriented studies and in a manner which resembles the organ committee orientation of SWOG. Our faculty's representation in scientific SWOG committees is constituted by individuals with expertise and commitment toward these areas of research. Accordingly, the translation of ideas into SWOG studies, and the incorporation of SWOG studies and those bf NCI designated high priority trials into WSU treatment priorities, are easily facilitated. Additionally, the unique demographics of our region and the cancer center commitment to the inclusion of minorities and women into clinical trials can be clearly identified in our recruitment of minorities (24%) and women (52%) into SWOG clinical trials. Our cancer center mission statement states that we are """"""""a unique, urban-based center of research, patient care and education, dedicated to the prevention, early detection, treatment and eventual eradication of cancer"""""""". This mission remains consistent with the overall mission of the SWOG cooperative group, enhancing our continued success in this research collaboration. In this challenging economic time and as a U10 member, it is acknowledged that monetary resources are not sufficient to completely fund the challenging work that we do. Despite this, it is the goal of WSU to continue our support at the level we are currently involved. Additionally, we will facilitate the education and success in our next generation of investigators, leading by example and commitment. Lawrence Flaherty, MD has been a SWOG member since 1986 and Co-Chairman of the SWOG Melanoma Committee and Co-Chair of the SWOG Melanoma Working Group since 1988 and 1990, respectively. As the Institutional PI since 1996 he has maintained the prominence and excellence of WSU as a SWOG full member institution.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wayne State University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9

Showing the most recent 10 out of 215 publications